Paxman AB (publ) (PAX.ST)
SEK 65.0
(0.0%)
SEK 65.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 8.33 Million SEK | 180.69% |
| 2022 | -10.32 Million SEK | 19.19% |
| 2021 | -12.77 Million SEK | 33.41% |
| 2020 | -19.18 Million SEK | -796.15% |
| 2019 | 2.75 Million SEK | 138.81% |
| 2018 | -7.1 Million SEK | -5.59% |
| 2017 | -6.72 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 9.81 Million SEK | -25.11% |
| 2024 Q1 | 13.1 Million SEK | 896.35% |
| 2023 Q3 | 7.36 Million SEK | 43.12% |
| 2023 FY | 8.33 Million SEK | 180.69% |
| 2023 Q1 | -2.53 Million SEK | 72.99% |
| 2023 Q2 | 5.14 Million SEK | 303.24% |
| 2023 Q4 | -1.64 Million SEK | -122.36% |
| 2022 Q1 | -6.2 Million SEK | -367.67% |
| 2022 Q4 | -9.37 Million SEK | -301.42% |
| 2022 Q3 | 4.65 Million SEK | 675.33% |
| 2022 Q2 | 600 Thousand SEK | 109.67% |
| 2022 FY | -10.32 Million SEK | 19.19% |
| 2021 Q1 | -3.65 Million SEK | 66.92% |
| 2021 Q2 | -5.46 Million SEK | -49.59% |
| 2021 Q3 | -5.25 Million SEK | 3.97% |
| 2021 Q4 | -1.32 Million SEK | 74.73% |
| 2021 FY | -12.77 Million SEK | 33.41% |
| 2020 Q1 | 2.56 Million SEK | 21.94% |
| 2020 Q3 | -4.23 Million SEK | 34.54% |
| 2020 Q4 | -11.05 Million SEK | -160.87% |
| 2020 FY | -19.18 Million SEK | -796.15% |
| 2020 Q2 | -6.47 Million SEK | -352.06% |
| 2019 Q4 | 2.1 Million SEK | 148.94% |
| 2019 FY | 2.75 Million SEK | 138.81% |
| 2019 Q1 | -489 Thousand SEK | 88.53% |
| 2019 Q2 | 293 Thousand SEK | 159.92% |
| 2019 Q3 | 846 Thousand SEK | 188.74% |
| 2018 Q3 | -303 Thousand SEK | 65.09% |
| 2018 Q4 | -4.26 Million SEK | -1307.59% |
| 2018 Q2 | -868 Thousand SEK | 47.84% |
| 2018 FY | -7.1 Million SEK | -5.59% |
| 2018 Q1 | -1.66 Million SEK | 66.0% |
| 2017 FY | -6.72 Million SEK | 0.0% |
| 2017 Q1 | -338 Thousand SEK | 0.0% |
| 2017 Q2 | 723 Thousand SEK | 313.91% |
| 2017 Q3 | -2.5 Million SEK | -446.2% |
| 2017 Q4 | -4.89 Million SEK | -95.53% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 110.702% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 91.952% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 91.952% |
| Arcoma AB | 2.56 Million SEK | -224.883% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 106.02% |
| BICO Group AB (publ) | -835.7 Million SEK | 100.997% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 66.649% |
| CellaVision AB (publ) | 130.3 Million SEK | 93.608% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 110.44% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 128.54% |
| C-Rad AB (publ) | 35.52 Million SEK | 76.554% |
| Duearity AB (publ) | -26.19 Million SEK | 131.806% |
| Dignitana AB (publ) | -17.36 Million SEK | 147.976% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 108.787% |
| Getinge AB (publ) | 2.41 Billion SEK | 99.655% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 112.254% |
| Iconovo AB (publ) | -45.89 Million SEK | 118.151% |
| Integrum AB (publ) | 4.03 Million SEK | -106.573% |
| Luxbright AB (publ) | -25.37 Million SEK | 132.827% |
| Mentice AB (publ) | -2.81 Million SEK | 395.705% |
| OssDsign AB (publ) | -130.49 Million SEK | 106.383% |
| Promimic AB (publ) | -9.22 Million SEK | 190.327% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 105.208% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 114.986% |
| ScandiDos AB (publ) | -14.64 Million SEK | 156.872% |
| Sectra AB (publ) | 428.38 Million SEK | 98.056% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 113.974% |
| Senzime AB (publ) | -134.14 Million SEK | 106.21% |
| SpectraCure AB (publ) | -20.44 Million SEK | 140.751% |
| Stille AB | 26.64 Million SEK | 68.738% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 100.216% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 90.928% |